C92.5
Acute myelomonocytic leukemia
Clinical Classification Guidelines
Inclusion Terms
- AML M4
- AML M4 Eo with inv(16) or t(16;16)
Medical Intelligence & Overview
Acute myelomonocytic leukemia, also known as AML M4, is a type of blood cancer characterized by the rapid growth of abnormal myeloid cells in the bone marrow and blood. This form of leukemia involves both myeloid and monocyte cell lines, leading to a complex disease that can affect various parts of the body. AML M4 with eosinophilia (AML M4 Eo), especially those with certain genetic abnormalities like inv(16) or t(16;16), forms a subtype with distinct features. This condition often progresses quickly and requires prompt medical attention.
Causes & Symptoms
Clinical Causes: Genetic mutations such as inv(16) or t(16;16), which involve specific chromosomal changes. Exposure to high levels of radiation or chemotherapy in the past. Environmental factors, including exposure to certain chemicals like benzene. Pre-existing blood disorders or other types of leukemia that may increase risk. Family history of leukemia or blood cancers.
Key Symptoms: Fatigue and weakness due to anemia. Fever and night sweats caused by immune system reactions. Unexplained weight loss. Easy bruising or bleeding because of low platelet counts. Frequent infections resulting from impaired immune function. Bone and joint pain. Enlargement of the liver or spleen (hepatosplenomegaly). Pale skin or pallor.
Diagnostic & Treatment
Diagnosis Path: Diagnosing AML M4 involves several steps to confirm the presence of leukemia and its specific subtype. These include: - Complete blood count (CBC) showing abnormal levels of white blood cells, red blood cells, and platelets. - Bone marrow biopsy, where a sample from the marrow is examined microscopically for abnormal myelomonocytic cells. - Cytogenetic analysis to identify genetic abnormalities such as inv(16) or t(16;16), which influence prognosis and treatment. - Flow cytometry to analyze cell surface markers, helping to determine the specific leukemia subtype. - Molecular testing for genetic mutations associated with AML.
Treatment Protocols: Treatment for AML M4, especially with genetic features like inv(16), typically involves aggressive therapy aimed at destroying leukemia cells and restoring healthy blood cell production. Common approaches include: - Chemotherapy, often starting with induction therapy to induce remission. - Targeted therapies that focus on specific genetic abnormalities. - Hematopoietic stem cell transplantation (bone marrow transplant) in eligible patients, which may offer a chance for long-term remission. - Supportive care to manage symptoms and prevent infections, such as transfusions and antibiotics. - Clinical trials exploring new treatment options for specific genetic subtypes.
Clinical Advice & FAQs
Billing Guidance
Is C92.5 a billable ICD-10 code?
Yes, C92.5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.5?
Clinical documentation must specify the nature of Acute myelomonocytic leukemia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference